Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817242 | 0.92 | PNMT (0.53) | PNMTCYP1A2FOLH1TAAR1CTBP2 | |
| SCHEMBL1817614 | 0.92 | PNMT (0.53) | PNMTCYP1A2FOLH1TAAR1CTBP2 | |
| SCHEMBL1817585 | 0.92 | CYP1A2 (0.50) | CYP1A2ANPEPRNPEPDNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL4639307 | 0.90 | PNMT (0.51) | PNMTCYP1A2FOLH1TAAR1CTBP2 | |
| Hydrochloric Acid SCHEMBL4619275 | 0.90 | PNMT (0.51) | PNMTCYP1A2FOLH1TAAR1CTBP2 | |
| SCHEMBL4991032 | 0.84 | PNMT (0.53) | PNMTANPEPRNPEPDNPEPMAPK1 | |
| SCHEMBL4987396 | 0.83 | PNMT (0.51) | PNMTFOLH1CTSBTAAR1CTBP2 | |
| SCHEMBL14885330 | 0.80 | CYP1A2 (0.55) | PNMTCYP1A2FOLH1CTBP2 | |
| SCHEMBL4989945 | 0.79 | PNMT (0.47) | PNMTCTSBTAAR1CTBP2 | |
| Methyl Alcohol SCHEMBL28745590 | 0.79 | PNMT (0.69) | PNMTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, OPRD1 | PNMT 2499/4885CYP1A2 395/4885ANPEP 148/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | PNMT 3457/4885CYP1A2 174/4885ANPEP 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.